Andrews Ben, Semler Matthew W, Muchemwa Levy, Kelly Paul, Lakhi Shabir, Heimburger Douglas C, Mabula Chileshe, Bwalya Mwango, Bernard Gordon R
Institute for Global Health, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Internal Medicine, School of Medicine, University of Zambia, Lusaka.
JAMA. 2017 Oct 3;318(13):1233-1240. doi: 10.1001/jama.2017.10913.
The effect of an early resuscitation protocol on sepsis outcomes in developing countries remains unknown.
To determine whether an early resuscitation protocol with administration of intravenous fluids, vasopressors, and blood transfusion decreases mortality among Zambian adults with sepsis and hypotension compared with usual care.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of 212 adults with sepsis (suspected infection plus ≥2 systemic inflammatory response syndrome criteria) and hypotension (systolic blood pressure ≤90 mm Hg or mean arterial pressure ≤65 mm Hg) presenting to the emergency department at a 1500-bed referral hospital in Zambia between October 22, 2012, and November 11, 2013. Data collection concluded December 9, 2013.
Patients were randomized 1:1 to either (1) an early resuscitation protocol for sepsis (n = 107) that included intravenous fluid bolus administration with monitoring of jugular venous pressure, respiratory rate, and arterial oxygen saturation and treatment with vasopressors targeting mean arterial pressure (≥65 mm Hg) and blood transfusion (for patients with a hemoglobin level <7 g/dL) or (2) usual care (n = 105) in which treating clinicians determined hemodynamic management.
The primary outcome was in-hospital mortality and the secondary outcomes included the volume of intravenous fluid received and receipt of vasopressors.
Among 212 patients randomized to receive either the sepsis protocol or usual care, 3 were ineligible and the remaining 209 completed the study and were included in the analysis (mean [SD] age, 36.7 [12.4] years; 117 men [56.0%]; 187 [89.5%] positive for the human immunodeficiency virus). The primary outcome of in-hospital mortality occurred in 51 of 106 patients (48.1%) in the sepsis protocol group compared with 34 of 103 patients (33.0%) in the usual care group (between-group difference, 15.1% [95% CI, 2.0%-28.3%]; relative risk, 1.46 [95% CI, 1.04-2.05]; P = .03). In the 6 hours after presentation to the emergency department, patients in the sepsis protocol group received a median of 3.5 L (interquartile range, 2.7-4.0 L) of intravenous fluid compared with 2.0 L (interquartile range, 1.0-2.5 L) in the usual care group (mean difference, 1.2 L [95% CI, 1.0-1.5 L]; P < .001). Fifteen patients (14.2%) in the sepsis protocol group and 2 patients (1.9%) in the usual care group received vasopressors (between-group difference, 12.3% [95% CI, 5.1%-19.4%]; P < .001).
Among adults with sepsis and hypotension, most of whom were positive for HIV, in a resource-limited setting, a protocol for early resuscitation with administration of intravenous fluids and vasopressors increased in-hospital mortality compared with usual care. Further studies are needed to understand the effects of administration of intravenous fluid boluses and vasopressors in patients with sepsis across different low- and middle-income clinical settings and patient populations.
clinicaltrials.gov Identifier: NCT01663701.
早期复苏方案对发展中国家脓毒症结局的影响尚不清楚。
确定与常规治疗相比,静脉输液、血管升压药和输血的早期复苏方案是否能降低赞比亚脓毒症和低血压成年患者的死亡率。
设计、地点和参与者:2012年10月22日至2013年11月11日期间,在赞比亚一家拥有1500张床位的转诊医院急诊科就诊的212例脓毒症(疑似感染加≥2项全身炎症反应综合征标准)和低血压(收缩压≤90mmHg或平均动脉压≤65mmHg)成年患者的随机临床试验。数据收集于2013年12月9日结束。
患者按1:1随机分为两组:(1)脓毒症早期复苏方案组(n = 107),包括静脉推注液体,同时监测颈静脉压、呼吸频率和动脉血氧饱和度,并使用血管升压药将平均动脉压维持在≥65mmHg,以及对血红蛋白水平<7g/dL的患者进行输血;(2)常规治疗组(n = 105),由治疗医生确定血流动力学管理方案。
主要结局是住院死亡率,次要结局包括静脉输液量和血管升压药的使用情况。
在212例随机接受脓毒症方案或常规治疗的患者中,3例不符合条件,其余209例完成研究并纳入分析(平均[标准差]年龄,36.7[12.4]岁;男性117例[56.0%];187例[89.5%]人类免疫缺陷病毒检测呈阳性)。脓毒症方案组106例患者中有51例(48.1%)发生住院死亡这一主要结局,而常规治疗组103例患者中有34例(33.0%)发生住院死亡(组间差异,15.1%[95%CI,2.0%-28.3%];相对风险,1.46[95%CI,1.04-2.05];P = 0.03)。在就诊于急诊科后的6小时内,脓毒症方案组患者静脉输液量中位数为3.5L(四分位间距,2.7-4.0L),而常规治疗组为2.0L(四分位间距,1.0-2.5L)(平均差异,1.2L[95%CI,1.0-1.5L];P < 0.)。脓毒症方案组15例患者(14.2%)和常规治疗组2例患者(1.9%)使用了血管升压药(组间差异,12.3%[95%CI,5.1%-19.4%];P < 0.001)。
在资源有限的环境中,对于大多数人类免疫缺陷病毒检测呈阳性的脓毒症和低血压成年患者,与常规治疗相比,静脉输液和血管升压药的早期复苏方案增加了住院死亡率。需要进一步研究以了解在不同低收入和中等收入临床环境及患者群体中,静脉推注液体和血管升压药对脓毒症患者的影响。
clinicaltrials.gov标识符:NCT01663701。